Country for PR: United Kingdom
Contributor: PR Newswire Europe
Friday, September 17 2021 - 04:24
PharmaZell and Novasep enter into exclusive negotiations in new drive to create a technology-driven leader for complex small molecules and ADCs of global scale
RAUBLING, Germany and LYON, France, Sept. 16, 2021 /PRNewswire-AsiaNet/ --

PharmaZell, the German producer of highly resilient and specialty APIs, and 
France-based Novasep, a leading CDMO focused on complex small molecules and 
ADCs have entered into exclusive negotiations to create a leading European 
platform in the attractive API manufacturing and CDMO space with a 
complementary set of differentiated technologies and highly diversified base of 
blue-chip pharma and biotech customers.  

Novasep is a leading CDMO player developing and manufacturing complex small 
molecules predominantly for pharma and biotech customers. The company leverages 
a wide range of differentiated technologies including high energy and cryogenic 
chemistries and industrial scale chromatography. It is a world leader in ADC 
and HPAPI, fast-growing targeted cancer therapy segments. 

Novasep's capabilities are highly complementary to PharmaZell's expertise in 
the manufacturing of complex APIs requiring special handling procedures or 
technologies. Combining the two businesses would create a leading, highly 
diversified, and highly differentiated API manufacturing and CDMO platform. The 
combined business would be able to draw from a comprehensive and broad 
technology suite for complex molecules and a global production footprint to 
support pharma and biotech customers over the complete lifecycle of a drug. The 
combined business would generate nearly €500m of revenues and employ close to 
2,000 employees across seven production and R&D sites in Europe (Germany, 
France and Italy), two sites in India and one in the US. 

The proposed transaction would be backed by PharmaZell's current majority 
shareholder Bridgepoint. Bridgepoint Group PLC is the world's leading quoted 
private assets growth investor focused on the middle-market with €27 billion 
AUM and a local presence in the US, Europe and China.

The proposed acquisition remains subject to the fulfilment of customary 
conditions precedent for this type of transaction including the information and 
consultation of works councils and other regulatory approvals.

The Press release is available in pdf.

Photo -  
Logo - 
PDF - 

Contact details:

SOURCE: Novasep